Trial Profile
Phase I trial of SNC 102 [acamprosate] for tardive dyskinesia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Feb 2014
Price :
$35
*
At a glance
- Drugs Acamprosate (Primary)
- Indications Drug-induced dyskinesia
- Focus Pharmacokinetics
- 24 Feb 2014 Status changed from planning to completed, based on information in a Synchroneuron media release.
- 08 Feb 2012 New trial record